Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target

Compare

481 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PHAT Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Phathom

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PHAT Stock 12 Month Forecast

Average Price Target

$19.88

▲(121.63%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Phathom Pharmaceuticals in the last 3 months. The average price target is $19.88 with a high forecast of $29.00 and a low forecast of $12.00. The average price target represents a 121.63% change from the last price of $8.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","23":"$23","30":"$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9,16,23,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.64,6.513846153846154,8.387692307692307,10.26153846153846,12.135384615384615,14.009230769230768,15.88307692307692,17.756923076923076,19.63076923076923,21.504615384615384,23.378461538461536,25.252307692307692,27.126153846153844,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.64,5.812307692307692,6.984615384615385,8.156923076923077,9.329230769230769,10.50153846153846,11.673846153846153,12.846153846153847,14.018461538461537,15.19076923076923,16.36307692307692,17.535384615384615,18.70769230769231,{"y":19.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.64,5.206153846153846,5.772307692307692,6.338461538461538,6.904615384615385,7.470769230769231,8.036923076923078,8.603076923076923,9.169230769230769,9.735384615384616,10.301538461538463,10.867692307692309,11.433846153846154,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.26,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.52,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$29.00

Average Price Target$19.88

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

0.33%

Upside

Reiterated

06/07/25

Phathom Pharmaceuticals' overall stock score reflects a challenging financial position with significant revenue growth offset by high net losses and financial instability. Positive developments in corporate events and strategic initiatives provide some optimism, but technical and valuation metrics indicate caution.

Chase KnickerbockerCraig-Hallum

Craig-Hallum

$12→$17

Buy

89.52%

Upside

Reiterated

06/09/25

Phathom Pharmaceuticals price target raised to $17 from $12 at Craig-HallumPhathom Pharmaceuticals price target raised to $17 from $12 at Craig-Hallum

Paul ChoiGoldman Sachs

Goldman Sachs

$10→$12

Hold

33.78%

Upside

Reiterated

06/09/25

Goldman Sachs Reaffirms Their Hold Rating on Phathom Pharmaceuticals (PHAT)

Matthew CaufieldH.C. Wainwright

H.C. Wainwright

$20

Buy

122.97%

Upside

Reiterated

06/09/25

Phathom Pharmaceuticals Receives Buy Rating Amidst FDA Approval and Market Optimism for VOQUEZNA

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$23→$29

Buy

223.30%

Upside

Reiterated

06/06/25

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor FitzgeraldPhathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald

Yatin SunejaGuggenheim

Guggenheim

$12

Buy

33.78%

Upside

Reiterated

06/06/25

Guggenheim Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT)

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$28

Buy

212.15%

Upside

Reiterated

06/06/25

Stifel expects Phathom to 'largely recover ground lost' after FDA grants claimStifel expects Phathom to 'largely recover ground lost' after FDA grants claim

Joseph StringerNeedham

Needham

$28

Buy

212.15%

Upside

Reiterated

06/06/25

Phathom Pharmaceuticals Gains Momentum with FDA Approval and Market Exclusivity for Voquezna

Glen SantangeloJefferies

Jefferies

$17→$13

Buy

44.93%

Upside

Reiterated

03/19/25

Phathom Pharmaceuticals: Favorable Risk/Reward Profile Amid Challenges and Growth Opportunities

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

0.33%

Upside

Reiterated

06/07/25

Chase KnickerbockerCraig-Hallum

Craig-Hallum

$12→$17

Buy

89.52%

Upside

Reiterated

06/09/25

Phathom Pharmaceuticals price target raised to $17 from $12 at Craig-HallumPhathom Pharmaceuticals price target raised to $17 from $12 at Craig-Hallum

Paul ChoiGoldman Sachs

Goldman Sachs

$10→$12

Hold

33.78%

Upside

Reiterated

06/09/25

Goldman Sachs Reaffirms Their Hold Rating on Phathom Pharmaceuticals (PHAT)

Matthew CaufieldH.C. Wainwright

H.C. Wainwright

$20

Buy

122.97%

Upside

Reiterated

06/09/25

Phathom Pharmaceuticals Receives Buy Rating Amidst FDA Approval and Market Optimism for VOQUEZNA

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$23→$29

Buy

223.30%

Upside

Reiterated

06/06/25

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor FitzgeraldPhathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald

Yatin SunejaGuggenheim

Guggenheim

$12

Buy

33.78%

Upside

Reiterated

06/06/25

Guggenheim Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT)

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$28

Buy

212.15%

Upside

Reiterated

06/06/25

Stifel expects Phathom to 'largely recover ground lost' after FDA grants claimStifel expects Phathom to 'largely recover ground lost' after FDA grants claim

Joseph StringerNeedham

Needham

$28

Buy

212.15%

Upside

Reiterated

06/06/25

Phathom Pharmaceuticals Gains Momentum with FDA Approval and Market Exclusivity for Voquezna

Glen SantangeloJefferies

Jefferies

$17→$13

Buy

44.93%

Upside

Reiterated

03/19/25

Phathom Pharmaceuticals: Favorable Risk/Reward Profile Amid Challenges and Growth Opportunities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Phathom Pharmaceuticals

1 Month

xxx

Success Rate

15/34 ratings generated profit

Average Return

-2.55%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.12% of your transactions generating a profit, with an average return of -2.55% per trade.

3 Months

xxx

Success Rate

10/16 ratings generated profit

Average Return

+17.35%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +17.35% per trade.

1 Year

Chase KnickerbockerCraig-Hallum

Success Rate

9/16 ratings generated profit

Average Return

+16.23%

reiterated a buy rating 3 days ago

Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +16.23% per trade.

2 Years

xxx

Success Rate

6/16 ratings generated profit

Average Return

-7.51%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -7.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PHAT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PHAT has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. PHAT average Analyst price target in the past 3 months is 19.88.

Each month's total comprises the sum of three months' worth of ratings.

PHAT Financial Forecast

PHAT Earnings Forecast

Next quarter’s earnings estimate for PHAT is -$0.90 with a range of -$1.11 to -$0.64. The previous quarter’s EPS was -$1.31. PHAT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.05% of the time in the same period. In the last calendar year PHAT has Outperformed its overall industry.

PHAT Sales Forecast

Next quarter’s sales forecast for PHAT is $36.38M with a range of $32.70M to $41.54M. The previous quarter’s sales results were $28.52M. PHAT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year PHAT has Outperformed its overall industry.

PHAT Stock Forecast FAQ

What is PHAT’s average 12-month price target, according to analysts?

Based on analyst ratings, Phathom Pharmaceuticals’s 12-month average price target is 19.88.

What is PHAT’s upside potential, based on the analysts’ average price target?

Phathom Pharmaceuticals has 121.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PHAT a Buy, Sell or Hold?

Phathom Pharmaceuticals has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Phathom Pharmaceuticals’s price target?

The average price target for Phathom Pharmaceuticals is 19.88. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $12.00. The average price target represents 121.63% Increase from the current price of $8.97.

What do analysts say about Phathom Pharmaceuticals?

Phathom Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of PHAT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target

PHAT Analyst Ratings

PHAT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Phathom Pharmaceuticals

PHAT Analyst Recommendation Trends

PHAT Financial Forecast

PHAT Earnings Forecast

PHAT Sales Forecast

PHAT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts